☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - September 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Dronedarone (Multaq®) has been accepted for restricted use in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation when conventional first-line anti-arrhythmic medicines are ineffective, contra-indicated or not tolerated. Treatment should also be started by a specialist.

Esomeprazole (Nexium®) has been accepted for restricted use for the treatment of gastro-oesophageal reflux disease (GORD) in children 1 to 11 years old when licensed doses of a generic proton pump inhibitor have been ineffective.

Agomelatine (Valdoxan®) has been rejected following a resubmission for the treatment of major depressive episodes in adults. the economic analysis was not sufficiently robust to gain acceptance.

Febuxostat (Adenuric®) has been accepted for restricted use in the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence, of tophus and/or gouty arthritis) when treatment with allopurinol is inadequate, not tolerated or contraindicated.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2010' by emailShare 'SMC Update - September 2010' on FacebookShare 'SMC Update - September 2010' on TwitterShare 'SMC Update - September 2010' on LinkedInShare 'SMC Update - September 2010' on reddit


No Comments to “SMC Update - September 2010”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.